Publications by authors named "V Curull"
Introduction: Neoadjuvant and adjuvant immune checkpoint blockade (ICB) have recently become standard of care in resectable non-small cell lung cancer (NSCLC). Yet, biomarkers that inform patients who benefit from this approach remain largely unknown. Here, we interrogated the tumor immune microenvironment (TIME) in early-stage NSCLC patients that underwent up-front surgery.
View Article and Find Full Text PDFObjective: We compared dexmedetomidine-remifentanil vs. propofol-remifentanil in terms of safety and quality during sedation for Endobronchial ultrasonography (EBUS).
Methods: A randomized, double-blind trial.
Epithelial-mesenchymal transition (EMT) is involved in the pathophysiology of lung cancer (LC) and COPD, and the latter is an important risk factor for LC. We hypothesised that the EMT gene expression profile and signalling cascade may differ in LC patients with COPD from those with no respiratory diseases. In lung tumour specimens obtained through video-assisted thoracoscopic surgery from LC (n=20, control group) and LC-COPD patients (n=30), gene expression (quantitative real-time PCR amplification) of EMT markers , , , , , , , , and was detected.
View Article and Find Full Text PDFArticle Synopsis
- Lung cancer risk is heightened in patients with chronic respiratory diseases like COPD, and this study investigates the plasma levels of microRNAs, redox balance, and cytokines in lung cancer patients with and without COPD.
- The analysis revealed increased levels of MDA-protein adducts and decreased GSH in lung cancer patients with COPD, alongside distinct microRNA expression patterns compared to controls, suggesting a complex interaction between these factors.
- The findings indicate that oxidative stress and antioxidant markers differ in lung cancer patients with respiratory diseases, highlighting their potential role in the development of lung tumors in these individuals.
The acquisition of driver mutations in non-tumoral cells appears to be very important during the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related mutations may not necessarily be present only in malignant cells, but also in histologically "healthy cells". to demonstrate the presence of or mutations in non-tumoral lung cells in subjects with ADC and negative mutational status.
View Article and Find Full Text PDF